A new institute at the University of Cambridge aims to revolutionise cancer care by using cutting edge analytics to maximize the use of big data sets collected from patients.
Patients in intensive care units are at significant risk of potentially life-threatening secondary infections, including from antibiotic-resistant bacteria such as MRSA and C. difficile. Now, a new test could identify those at greatest risk – and speed up the development of new therapies to help at-risk patients.
More research needs to be done to understand whether CRISPR-Cas9 – molecular ‘scissors’ that make gene editing a possibility – may inadvertently increase cancer risk in cells, according to researchers from the University of Cambridge and the Karolinska Institutet.
Business Secretary Greg Clark today announced funding for a series of ambitious technology projects that will transform the way medicines are discovered, enabling the pharmaceutical industry to develop groundbreaking drugs faster, cheaper and better than ever before.
Almost 30 years on from the discovery of the genetic defect that causes cystic fibrosis, treatment options are still limited and growing antibiotic resistance presents a grave threat. Now, a team of researchers from across Cambridge, in a major new centre supported by the Cystic Fibrosis Trust, hopes to turn fortunes around.
The past few years has seen an explosion in the number of studies using organoids – so-called ‘mini organs’. While they can help scientists understand human biology and disease, some in the field have questioned their usefulness. But as the field matures, we could see their increasing use in personalised and regenerative medicine.
Scientists have shown in mice that skin cells re-programmed into brain stem cells, transplanted into the central nervous system, help reduce inflammation and may be able to help repair damage caused by multiple sclerosis (MS).
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs. This discovery, led by researchers at the University of Cambridge, was aided by Eve, an artificially-intelligent ‘robot scientist’.
Kate Gross was just 36 years old when she died of cancer. Researchers at Cambridge – including her husband – are trying to ensure that others receive their diagnoses early enough to stop their cancer.
Cambridge Academy of Therapeutic Sciences receives Wellcome funding to support translational research05 Dec 2017
The Cambridge Academy of Therapeutic Sciences (CATS) has been awarded £1million over two years by Wellcome as a part of a new scheme to find new ways to translate scientific discoveries into real world impact.